Phase 2 Study Finds Tildrakizumab Effective for PsA Manifestations
FDA Grants Empagliflozin Breakthrough Therapy Designation in HFpEF
Children, Adolescents Considered Obese May Have Greater Risk of NAFLD
The Green Environment, Air Pollution, and Respiratory Health